Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 4Gynecologic 2CNS 2Gastrointestinal 1

Conditions

Trophoblastic Tumor, Placental Site 1Ovarian Neoplasms 1Gestational Trophoblastic Disease 1Fallopian Tube Neoplasms 1Choriocarcinoma 1

Interventions

Paclitaxel 233Carboplatin 217Bevacizumab 139Cisplatin 136pembrolizumab 89Gemcitabine 69olaparib 54Docetaxel 47Topotecan 44Radiotherapy 43liposomal doxorubicin 41Taxes 41niraparib 38Cyclophosphamide 36Doxorubicin 30Drug Therapy 29Letrozole 28Nivolumab 27Magnetic Resonance Spectroscopy 25Immunoglobulin G 25Disulfides 24Oxaliplatin 23Albumin-Bound Paclitaxel 23durvalumab 22apatinib 21Etoposide 21Brachytherapy 21lenvatinib 20camrelizumab 20Specimen Handling 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × carotuximab × Gynecologic × Clear all
NCT02664961 2019-07-23

Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)

Tracon Pharmaceuticals Inc.

Phase 2 Terminated
3 enrolled 11 charts
Gynecologic

Choriocarcinoma, Trophoblastic Tumor, Placental Site, Gestational Trophoblastic Disease

NCT01381861 2019-03-05

Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

Tracon Pharmaceuticals Inc.

Phase 2 Completed
23 enrolled 12 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡